Oppenheimer & Co. Inc. Trims Position in Capricor Therapeutics, Inc. $CAPR

Oppenheimer & Co. Inc. cut its holdings in shares of Capricor Therapeutics, Inc. (NASDAQ:CAPR) by 40.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 80,813 shares of the biotechnology company’s stock after selling 54,600 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in Capricor Therapeutics were worth $2,332,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the business. GSA Capital Partners LLP bought a new position in Capricor Therapeutics during the 3rd quarter valued at $1,555,000. Moody Aldrich Partners LLC bought a new position in Capricor Therapeutics during the 4th quarter valued at $6,025,000. Pier Capital LLC boosted its stake in Capricor Therapeutics by 35.0% during the 3rd quarter. Pier Capital LLC now owns 496,554 shares of the biotechnology company’s stock valued at $3,580,000 after acquiring an additional 128,837 shares during the last quarter. AlphaQuest LLC boosted its stake in Capricor Therapeutics by 396.2% during the 3rd quarter. AlphaQuest LLC now owns 30,025 shares of the biotechnology company’s stock valued at $216,000 after acquiring an additional 23,974 shares during the last quarter. Finally, Russell Investments Group Ltd. boosted its stake in Capricor Therapeutics by 122.2% during the 3rd quarter. Russell Investments Group Ltd. now owns 5,066 shares of the biotechnology company’s stock valued at $37,000 after acquiring an additional 2,786 shares during the last quarter. 21.68% of the stock is owned by hedge funds and other institutional investors.

Capricor Therapeutics Stock Up 8.4%

Shares of NASDAQ:CAPR opened at $33.50 on Tuesday. Capricor Therapeutics, Inc. has a fifty-two week low of $4.30 and a fifty-two week high of $40.37. The firm has a 50-day simple moving average of $31.11 and a 200 day simple moving average of $22.76. The company has a market cap of $1.94 billion, a PE ratio of -14.82 and a beta of 0.48.

Capricor Therapeutics (NASDAQ:CAPR) last announced its quarterly earnings data on Thursday, March 12th. The biotechnology company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.11). As a group, research analysts forecast that Capricor Therapeutics, Inc. will post 0.01 EPS for the current fiscal year.

Insider Transactions at Capricor Therapeutics

In related news, Director Karimah Es Sabar sold 7,529 shares of the business’s stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $32.00, for a total transaction of $240,928.00. Following the completion of the sale, the director owned 7,529 shares of the company’s stock, valued at $240,928. This represents a 50.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Anthony Bergmann sold 25,000 shares of the stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $31.70, for a total transaction of $792,500.00. Following the completion of the sale, the chief financial officer directly owned 8,223 shares in the company, valued at approximately $260,669.10. This trade represents a 75.25% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 172,529 shares of company stock valued at $5,302,440. Insiders own 9.20% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have commented on the stock. B. Riley Financial increased their price objective on shares of Capricor Therapeutics from $50.00 to $63.00 and gave the company a “buy” rating in a research note on Friday, March 13th. HC Wainwright reiterated a “buy” rating and set a $60.00 price objective on shares of Capricor Therapeutics in a research note on Tuesday, March 10th. Wall Street Zen cut shares of Capricor Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, January 11th. Cantor Fitzgerald set a $62.00 price target on shares of Capricor Therapeutics and gave the stock an “overweight” rating in a research report on Friday, March 13th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $58.00 price target (up from $45.00) on shares of Capricor Therapeutics in a report on Friday, March 13th. Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $46.09.

Capricor Therapeutics Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.